Sign inJoin waitlistJoin the waitlist

Kirk Knowlton

Adjunct Professor · Univ of Utah Sch of Med

Credentials: · · · · · ·

History

Univ of Utah Sch of Med
Present

Cardiovascular Disease
1987–1990
Internal Medicine
1984–1987
University of Utah School of Medicine
1980–1984

Research

Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response
Review · The FASEB Journal · 1991 · 722 citations
Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell…
Journal of Biological Chemistry · 1990 · 556 citations
Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy
Nature Medicine · 1999 · Last of 7 authors · 424 citations

Jeffrey Anderson
62 papers
Brent Muhlestein
58 papers
VL
Viet Le
38 papers
Lincoln Nadauld
26 papers
DL
Donald Lappe
21 papers
HH
Hilma Holm
20 papers
Jared Bunch
11 papers
Adrian Hernandez
8 papers
DingDing Xiong
8 papers
William Jones
8 papers
CB
Catherine Benziger
7 papers
David Min
7 papers

Grants

Training in Cardiovascular Physiology and Pharmacology
National Heart, Lung, and Blood Institute · T32
Contact PI · $2.6M · University of California, San Diego
1979–2018
Role of mTOR, a Component of the Akt Pathway, in Regulating Cardiac Function
National Heart, Lung, and Blood Institute · R01
Contact PI · $729.5K · University of California, San Diego
2005–2015
Molecular Pathways for Hypertrophy and Cardiomyopathy
National Heart, Lung, and Blood Institute · P01
Contact PI · $15.4M · University of California, San Diego
1992–2014
Cardiac SOCS Proteins: A Role in Enterovirus Infection
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.4M · University of California, San Diego
1998–2009

Clinical trials

Assessment of Patients With suspeCted Coronary Artery Disease by Coronary calciUm fiRst strATegy vErsus Usual Care Approach.
Principal investigator · Terminated
Intermountain Health Care, Inc.
2019–2023
Pilot and Feasibility Study of a MAWDS (Medications, Activity, Weight, Diet and Symptoms) Heart Failure Mobile Platform
Principal investigator · Completed
Intermountain Health Care, Inc.
2017–2018
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
Site PI · Recruiting
Intermountain Health Care, Inc.
2025–2028